Correction to: Statin Therapy in Metabolic Syndrome and Hypertension Post-JUPITER: What is the Value of CRP? (Current Atherosclerosis Reports, (2011), 13, 1, (31-42), 10.1007/s11883-010-0143-2);Statin therapy in metabolic syndrome and hypertension post-JUPITER: What is the value of CRP?

Current Atherosclerosis Reports

Volumn 13, Issue 1, 2011, Pages 31-42

  Devaraj, Sridevi ^a,b   Siegel, David ^a,b   Jialal, Ishwarlal ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; CRP; Endothelial dysfunction; Hypertension; Inflammation; Metabolic syndrome; Monocytes; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; COLESTYRAMINE; FOSINOPRIL; GEMFIBROZIL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; PROSTACYCLIN; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL OBESITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROTHROMBOSIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; LOW FAT DIET; METABOLIC SYNDROME X; MONOCYTE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 79551554869     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-019-0768-8     Document Type: Erratum

References (51)

1. R Ross 1999 Atherosclerosis: an inflammatory disease's Engl J Med 340 115 26 1:STN:280:DyaK1M%2FptFSqtQ%3D%3D 10.1056/NEJM199901143400207 (Pubitemid 29054847)
2. GK Hansson P Libby 2006 The immune response in atherosclerosis: a double-edged sword Nat Rev Immunol 6 508 19 1:CAS:528:DC%2BD28XmtFegsLc%3D 10.1038/nri1882 16778830 (Pubitemid 43980523)
3. S Verma PE Szmitko PM Ridker 2005 C-reactive protein comes of age Nat Clin Pract Cardiovasc Med 2 29 36 1:CAS:528:DC%2BD2MXlslGmt7o%3D 10.1038/ncpcardio0074 16265340 (Pubitemid 40823207)
4. S Verma S Devaraj I Jialal 2006 Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis Circulation 113 2135 50 16671184
5. PM Ridker 2003 High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention Am J Cardiol 92 17K 22K 1:CAS:528:DC%2BD3sXnvVSht70%3D 10.1016/S0002-9149(03)00774-4 12948872
6. PM Ridker JE Buring J Shih M Matias CH Hennekens 1998 Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women Circulation 98 731 3 1:CAS:528:DyaK1cXlvVyjtbY%3D 9727541
7. S Devaraj U Singh I Jialal 2009 The evolving role of C-reactive protein in atherothrombosis Clin Chem 55 229 38 1:CAS:528:DC%2BD1MXhvVWks74%3D 10.1373/clinchem.2008.108886 19095731 This review article details the proatherogenic effects of CRP on different cells in atherosclerosis
8. S Devaraj JM Yun G Adamson, et al. 2009 C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction Cardiovasc Res 84 3 479 84 1:CAS:528:DC%2BD1MXhsVGnu77N 10.1093/cvr/cvp249 19620133
9. TW Hein U Singh J Vasquez-Vivar, et al. 2009 Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo Atherosclerosis 206 1 61 8 1:CAS:528:DC%2BD1MXhtVKlsLjM 10.1016/j.atherosclerosis.2009.02.002 19268941
10. S Valleggi S Devaraj MR Dasu I Jialal 2010 C-reactive protein adversely alters the protein-protein interaction of the endothelial isoform of nitric oxide synthase Clin Chem 56 8 1345 8 1:CAS:528:DC%2BC3cXhtVahsb%2FM 10.1373/clinchem.2009.142364 20472823
11. U Singh S Devaraj J Vasquez-Vivar I Jialal 2007 C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling J Mol Cell Cardiol 43 6 780 91 1:CAS:528:DC%2BD2sXhtlyrtbfK 10.1016/j.yjmcc.2007.08.015 17942113 (Pubitemid 350166380)
12. SK Venugopal S Devaraj I Jialal 2003 C-reactive protein decreases prostacyclin release from human aortic endothelial cells Circulation 108 1676 8 1:CAS:528:DC%2BD3sXns1Cgu7o%3D 10.1161/01.CIR.0000094736.10595.A1 14504187 (Pubitemid 37243652)
13. J Cermak NS Key RR Bach, et al. 1993 C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor Blood 82 513 20 1:CAS:528:DyaK3sXlsFOltrY%3D 8329706
14. S Devaraj MR Dasu U Singh, et al. 2009 C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo Atherosclerosis 203 1 67 74 1:CAS:528:DC%2BD1MXis1Cjs78%3D 10.1016/j.atherosclerosis.2008.05.060 18621373
15. U Singh S Devaraj I Jialal 2009 C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes Clin Chem 55 361 4 1:CAS:528:DC%2BD1MXhvVWksL0%3D 10.1373/clinchem.2008.109207 19074520
16. S Devaraj JM Yun C Duncan-Staley I Jialal 2009 C-reactive protein induces M-CSF release and macrophage proliferation J Leukoc Biol 85 2 262 7 1:CAS:528:DC%2BD1MXhslelurk%3D 10.1189/jlb.0808458 19008293
17. U Singh MR Dasu PG Yancey A Afify S Devaraj I Jialal 2008 Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats J Lipid Res 49 1015 23 1:CAS:528:DC%2BD1cXltFSlt7s%3D 10.1194/jlr.M700535-JLR200 18245817
18. HD Danenberg AJ Szalai RV Swaminathan, et al. 2003 Increased thrombosis after arterial injury in human C-reactive proteintransgenic mice Circulation 108 512 5 1:CAS:528:DC%2BD3sXlvVWqsbk%3D 10.1161/01.CIR.0000085568.13915.1E 12874178 (Pubitemid 36961161)
19. MB Pepys GM Hirschfield GA Tennent, et al. 2006 Targeting C-reactive protein for the treatment of cardiovascular disease Nature (Lond) 440 1217 21 1:CAS:528:DC%2BD28XjvVGltLY%3D 10.1038/nature04672
20. S Devaraj U Singh I Jialal 2009 Human C-reactive protein and the metabolic syndrome Curr Opin Lipidol 20 3 182 9 1:CAS:528:DC%2BD1MXls1Gltbc%3D 10.1097/MOL.0b013e32832ac03e 19369869
21. RH Eckel SM Grundy PZ Zimmet 2005 The metabolic syndrome Lancet 365 1415 1428 1:CAS:528:DC%2BD2MXjsVegtbg%3D 10.1016/S0140-6736(05)66378-7 15836891 (Pubitemid 40523737)
22. KG Alberti RH Eckel SM Grundy, et al. 2009 International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 120 16 1640 5 1:CAS:528:DC%2BD1MXht1OrtrrK 10.1161/CIRCULATIONAHA.109.192644 19805654
23. RH Eckel KG Alberti SM Grundy PZ Zimmet 2010 The metabolic syndrome Lancet 375 9710 181 3 10.1016/S0140-6736(09)61794-3 20109902
24. PM Ridker PW Wilson SM Grundy 2004 Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109 2818 2825 1:CAS:528:DC%2BD2cXksF2lu74%3D 10.1161/01.CIR.0000132467.45278.59 15197153 (Pubitemid 38780294)
25. I Jialal S Devaraj 2009 Statin therapy for the metabolic syndrome: the evidence base Metab Syndr Relat Disord 7 5 393 6 1:CAS:528:DC%2BD1MXht1Whu7jK 10.1089/met.2009.0705.edi 19731996
26. JS Yudkin M Kumari SE Humphries, et al. 2000 Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148 209 214 1:CAS:528:DC%2BD3cXosVymtw%3D%3D 10.1016/S0021-9150(99)00463-3 10657556 (Pubitemid 30064452)
27. A Festa R D'Agostino Jr G Howard, et al. 2004 Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS) Circulation 102 42
28. S Devaraj J Rogers I Jialal 2007 Statins and biomarkers of inflammation Curr Atheroscler Rep 9 1 33 41 1:CAS:528:DC%2BD2sXpt1ejs74%3D 10.1007/BF02693938 17169243 (Pubitemid 46075737)
29. I Jialal D Stein D Balis, et al. 2001 Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels Circulation 103 15 1933 5 1:CAS:528:DC%2BD3MXjslKks7Y%3D 11306519
30. PM Ridker E Danielson AH Francisco, et al. 2008 Rosuvastatin to prevent vascular events in men and women with elevated CRP N Engl J Med 359 2195 2207 1:CAS:528:DC%2BD1cXhtl2gurnL 10.1056/NEJMoa0807646 18997196
31. PM Ridker E Danielson AH Francisco, et al. 2009 Reduction in CRP and LDL-C and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 1175 82 1:CAS:528: DC%2BD1MXktV2gsL8%3D 10.1016/S0140-6736(09)60447-5 19329177 This is the first primary prevention trial showing benefit of rosuvastatin in decreasing cardiovascular events in patients with high CRP levels
32. J Genest R McPherson J Frohlich, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult: 2009 recommendations Can J Cardiol 25 567 579 1:CAS:528:DC%2BD1MXhtlynsLvF 19812802 These are the new guidelines from the Canadian Cardiovascular Society showing the utility of hsCRP measurements in those with intermediate risk
33. C Chrysohoou DB Panagiotakos C Pitsavos, et al. 2010 Renal function, cardiovascular disease risk factors' prevalence and 5-year disease incidence; the role of diet, exercise, lipids and inflammation markers: the ATTICA study QJM 103 413 22 1:STN:280:DC%2BC3czlsVWrsA%3D%3D 10.1093/qjmed/hcq045 20375102
34. ND Wong VA Lopez G L'Italien, et al. 2007 Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004 Arch Intern Med 167 2431 6 10.1001/archinte.167.22.2431 18071164 (Pubitemid 350254901)
35. S Mangat S Agarwal C Rosendorff 2007 Do statins lower blood pressure? J Cardiovasc Pharmacol Ther 12 112 23 1:CAS:528:DC%2BD2sXnsFSrtro%3D 10.1177/1074248407300380 17562781 (Pubitemid 46836325)
36. S Wolfrum KS Jensen JK Liao 2003 Endothelium-dependent effects of statins Arterioscler Thromb Vasc Biol 23 729 36 1:CAS:528:DC%2BD3sXjtlaktLw%3D 10.1161/01.ATV.0000063385.12476.A7 12615672 (Pubitemid 36566160)
37. S Wassmann A Faul B Hennen, et al. 2003 Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function Circ Res 93 e98 103 1:CAS:528:DC%2BD3sXotlejs7Y%3D 10.1161/01.RES.0000099503.13312.7B 14551237
38. RR Williams SC Hunt PN Hopkins, et al. 1988 Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension JAMA 259 3579 86 1:STN:280:DyaL1c3jtVyisQ%3D%3D 10.1001/jama.259.24.3579 3373705
39. JG O'Meara SL Kardia JJ Armon, et al. 2004 Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study Arch Intern Med 164 12 1313 8 10.1001/archinte.164.12.1313 15226165 (Pubitemid 38828882)
40. O Hernández-Perera D Pérez-Sala J Navarro-Antolín, et al. 1998 Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells J Clin Invest 101 2711 9 10.1172/JCI1500 9637705
41. G Nickenig AT Bäumer Y Temur, et al. 1999 Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men Circulation 100 2131 4 1:CAS:528:DyaK1MXotFajsbY%3D 10571970
42. S Verma CH Wang SH Li, et al. 2002 A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis Circulation 106 8 913 9 1:CAS:528:DC%2BD38XntlSqsrY%3D 10.1161/01.CIR. 0000029802.88087.5E 12186793 (Pubitemid 34925323)
43. V Dauphinot F Roche MP Kossovsky, et al. 2009 C-reactive protein implications in new-onset hypertension in a healthy population initially aged 65 years: the Proof study J Hypertens 27 4 736 43 1:CAS:528:DC%2BD1MXjtlOlurw%3D 10.1097/HJH.0b013e328326f801 19516173
44. A Virdis L Ghiadoni Y Plantinga, et al. 2007 C-reactive protein and hypertension: is there a causal relationship? Curr Pharm Des 13 1693 8 1:CAS:528:DC%2BD2sXntVOiu7s%3D 10.2174/138161207780831365 17584099 (Pubitemid 46979723)
45. C Borghi A Dormi M Veronesi, et al. 2004 Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study Am Heart J 148 285 92 1:CAS:528:DC%2BD2cXmslOhsL0%3D 10.1016/j.ahj.2004.02.003 15308998 (Pubitemid 39092793)
46. P Strazzullo SM Kerry A Barbato, et al. 2007 Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials Hypertension 49 792 8 1:CAS:528:DC%2BD2sXivVamt7w%3D 10.1161/01.HYP.0000259737.43916.42 17309949 (Pubitemid 351664226)
47. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
48. PS Sever B Dahlöf NR Poulter, et al. 2003 Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled tria Lancet 361 1149 58 1:CAS:528:DC%2BD3sXis1yqu7o%3D 10.1016/S0140-6736(03)12948-0 12686036 (Pubitemid 36398384)
49. DE King AG Mainous 3rd BM Egan M Player ME Geesey 2007 Use of statins and blood pressure Am J Hypertens 20 937 41 1:CAS:528:DC%2BD2sXpvF2qt7g%3D 10.1016/j.amjhyper.2007.03.018 17765132 (Pubitemid 47313622)
50. L Terzoli L Mircoli R Raco AU Ferrari 2005 Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors J Cardiovasc Pharmacol 46 310 5 1:CAS:528:DC%2BD2MXovVKrt7k%3D 10.1097/01.fjc.0000175432.56789.e6 16116336 (Pubitemid 41262833)
51. PM Ridker J Macfayden M Cressman RJ Glynn 2010 Efficacy of Rosuvastatin among men and women with moderate CKD and elevated hsCRP J Am Coll Cardiol 55 1266 73 1:CAS:528:DC%2BC3cXpvFSqu7c%3D 10.1016/j.jacc.2010.01.020 20206456 This is the first study to show that rosuvastatin is effective in reducing first cardiovascular events in those with CKD and elevated CRP